Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

Giovam Battista Rini, Francesca Maria Tumminello, Giuseppe Badalamenti, Gaetano Leto, Lorena Incorvaia, Nicolo' Gebbia, Marilena Crescimanno, Carla Flandina, Lorena Incorvaia, Giuseppe Badalamenti, Nicola Gebbia, Giovambattista Rini, Giovambattista Rini, Carla Flandina, Francesca M. Tumminello, Marilena Crescimanno, Gaetano Leto

Risultato della ricerca: Article

87 Citazioni (Scopus)

Abstract

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy blood donors (HS) of both sex (25 female and 23 male). Activin A serum concentrations were significantly increased in BC or PC patients as compared to OP (P < 0.0001) or BPH (P = 0.045), respectively, or to sex matched HS (P < 0.0001). Additionally, these levels resulted more elevated in PC patients as compared to BC patients (P = 0.032). Interestingly, Activin A was significantly higher in BM+ patients than in BM- patients (BC, P = 0.047; PC, P = 0.016). In BC patients, a significant correlation was observed only between Activin A and number of bone metastases (P = 0.0065) while, in PC patients, Activin A levels were strongly correlated with the Gleason score (P = 0.011) or PSA levels (P = 0.0001) and, to a lessen extent, with the number of bone metastases (P = 0.056). Receiver operating characteristic curve (ROC) analysis showed a fair diagnostic accuracy of Activin A to discriminate between BM+ and BM- patients (BC: AUC = 0.71 +/- 0.09, P = 0.03; PC: AUC = 0.73 +/- 0.081, P = 0.005). These findings indicate that Activin A may be implicated in the pathogenesis of bone metastasis. Therefore, this cytokine may be considered a novel potential target for a more selective therapeutic approach in the treatment of skeletal metastasis and may be also useful as additional biochemical marker of metastatic bone disease.
Lingua originaleEnglish
pagine (da-a)117-122
Numero di pagine6
RivistaCLINICAL &amp; EXPERIMENTAL METASTASIS
Volume23
Stato di pubblicazionePublished - 2006

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Activin A circulating levels in patients with bone metastasis from breast or prostate cancer'. Insieme formano una fingerprint unica.

  • Cita questo